Welcome to our dedicated page for BioNTech SE SEC filings (Ticker: BNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BioNTech SE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BioNTech SE's regulatory disclosures and financial reporting.
BioNTech SE is using a 2026 strategic update to highlight its shift toward becoming a multi-product oncology company while relying on its COVID-19 franchise and strong balance sheet. The company expects seven late-stage oncology data readouts in 2026 and plans to have 15 Phase 3 clinical trials ongoing by year-end, across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies. By 2030+, BioNTech anticipates at least 17 late-stage or pivotal data readouts that could support multiple product launches in major tumors such as lung, breast, gynecologic and head and neck cancers.
Financially, BioNTech reported approximately €17.2 billion in cash, cash equivalents and security investments as of December 31, 2025 and in November 2025 raised its 2025 revenue guidance to €2.6–2.8 billion while lowering expense guidance ranges. For 2026, it anticipates a modest decline in Comirnaty revenues and does not expect to recognize revenues from oncology product sales, while revenues from its Bristol Myers Squibb collaboration are expected to be broadly in line with 2025.
BioNTech SE reports that it has completed its exchange offer for all outstanding shares of CureVac N.V., following the expiration of the subsequent offering period. This means CureVac is now being acquired by BioNTech through a share-exchange structure rather than a cash-only deal. The company states that this step closes the acquisition process and is intended to strengthen BioNTech’s position in the mRNA field. The press release describing the transaction is included as an exhibit and this report is incorporated by reference into BioNTech’s existing Form F-4 registration statement.
BioNTech SE submitted a Form 6-K reporting that it issued a press release on November 26, 2025 about its exchange offer for all outstanding shares of CureVac N.V.. The press release announces the results of CureVac’s extraordinary general meeting and the calculation of the exchange ratio for the offer.
The filing states that this Form 6-K is incorporated by reference into BioNTech’s Form F-4 registration statement. The attached press release, filed as Exhibit 99.1, highlights progress on the exchange offer and notes a December 3, 2025 at 9:00 a.m. Eastern Time expiration for the offer.
BioNTech SE filed a Form 6‑K noting it hosted an edition of its Innovation Series R&D Day on November 11, 2025, providing an overview of strategy and clinical progress across its pipeline.
The related presentation is attached as Exhibit 99.1. The filing is signed by Chief Financial Officer Ramon Zapata‑Gomez and Chief Operating Officer Dr. Sierk Poetting.
BioNTech SE submitted a Form 6‑K as a foreign private issuer to provide investors with a development update and its latest financial information. On November 3, 2025, the company reported its financial results for the three and nine months ended September 30, 2025, and prepared interim condensed consolidated financial statements for that period. These financial statements, along with an operating and financial review and prospects section, are included as Exhibit 99.1 to the report and are deemed filed under the Securities Exchange Act. The filing is signed on behalf of BioNTech SE by its Chief Financial Officer and Chief Operating Officer.
BioNTech SE furnished a Form 6‑K announcing its third quarter 2025 financial results and corporate update. The company scheduled a conference call for 8:00 am EST on November 3, 2025 to discuss the results. A press release and presentation were provided as Exhibits 99.1 and 99.2 and are incorporated by reference. The materials are designated as furnished and not deemed filed under the Exchange Act unless specifically referenced in a future filing.
BioNTech SE announced the commencement of its public exchange offer for all outstanding shares of CureVac N.V., as disclosed in a press release furnished as Exhibit 99.1.
The report states this 6‑K is deemed filed and incorporated by reference into BioNTech’s registration statement on Form F-4 (File No. 333-289468) and its Forms S-8 (File Nos. 333-277105, 333-269740, 333-253263) from the filing date.
BioNTech SE filed an amended Form F-4 for an exchange offer to acquire all outstanding ordinary shares of CureVac N.V.. Each CureVac share will be exchanged for a number of BioNTech ADSs equal to $5.4641 divided by the 10‑day VWAP of BioNTech ADSs, subject to a collar that fixes the exchange ratio at 0.04318 if the VWAP is ≥ $126.55 or 0.06476 if ≤ $84.37.
The offer is scheduled to expire at 9:00 a.m. (New York City time) on December 3, 2025, unless extended. A minimum of 80% of CureVac’s issued and outstanding capital must be tendered (which may be reduced to 75% in certain circumstances). Shareholders representing approximately 57% of CureVac shares have entered tender and support agreements. Following acceptance, a subsequent offering period of at least 10 business days will be provided.
After the offer, a post‑offer reorganization is planned so that BioNTech becomes the sole owner of CureVac’s business. CureVac holders who do not tender will receive the same consideration in that process, though amounts received there may be subject to 15% Dutch dividend withholding tax in certain cases. Delivery of ADSs is expected about 10 business days after each required German capital increase becomes effective and could take up to three weeks or more.
BioNTech SE filed a Form 6‑K to inform investors that on October 1, 2025 it hosted its second AI Day together with its artificial intelligence company InstaDeep Ltd. This event is part of BioNTech’s “Innovation Series” and provided an overview of its AI strategy, its AI capabilities, and how AI is applied across BioNTech’s product pipeline and internal processes.
The related investor presentation, offering more detail on these AI initiatives, is furnished as Exhibit 99.1 to the report.
BioNTech SE filed a Form 6-K noting that it and Bristol Myers Squibb have presented interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) in extensive-stage small cell lung cancer. The investigational bispecific antibody targets PD-L1 and VEGF-A and is being evaluated in combination with chemotherapy. According to the attached press release description, the interim Phase 2 data show encouraging antitumor activity in this patient population.